Cargando…

Current and future treatment options for MET exon 14 skipping alterations in non-small cell lung cancer

It has been over three decades since the hepatocyte growth factor (HGF) ligand and its receptor MET proto-oncogene (MET) pathway was established as promoting cancer growth and metastasis. MET exon 14 skipping (METex14) alterations occur in 3–4% of all non-small cell lung cancer (NSCLC) patients, typ...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hong, Lingzhi, Zhang, Jianjun, Heymach, John V., Le, Xiuning
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7890719/ https://www.ncbi.nlm.nih.gov/pubmed/33643443 http://dx.doi.org/10.1177/1758835921992976

Ejemplares similares

Landscape and Clonal Dominance of Co-occurring Genomic Alterations in Non–Small-Cell Lung Cancer Harboring MET Exon 14 Skipping
por: Le, Xiuning, et al.
Publicado: (2021)

Lung Cancer with MET exon 14 Skipping Mutation: Genetic Feature, Current Treatments, and Future Challenges
por: Fujino, Toshio, et al.
Publicado: (2021)

Safety of Tepotinib in Patients With MET Exon 14 Skipping NSCLC and Recommendations for Management
por: Veillon, Remi, et al.
Publicado: (2022)

Tepotinib for advanced non-small-cell lung cancer with MET exon 14 skipping mutations
por: Błaszkowska, M., et al.
Publicado: (2022)

Non-small cell lung cancer with MET exon 14 skip mutation: case report
por: Clough, Wolfgang, et al.
Publicado: (2022)

Non-small cell lung cancer with MET exon 14 skipping alteration responding to immunotherapy: a case report
por: Chen, Zhuxing, et al.
Publicado: (2021)

A narrative review of MET inhibitors in non-small cell lung cancer with MET exon 14 skipping mutations
por: Santarpia, Mariacarmela, et al.
Publicado: (2021)

TRLS-03. Intracranial activity of tepotinib in patients with MET exon 14 (METex14) skipping NSCLC enrolled in VISION
por: Bestvina, Christine M, et al.
Publicado: (2021)

SYST-06 INTRACRANIAL ACTIVITY OF TEPOTINIB IN PATIENTS WITH MET EXON 14 (METEX14) SKIPPING NSCLC ENROLLED IN VISION
por: Leighl, Natasha, et al.
Publicado: (2022)

Clinicopathologic and Imaging Features of Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations
por: Digumarthy, Subba R., et al.
Publicado: (2019)

Spotlight on Tepotinib and Capmatinib for Non-Small Cell Lung Cancer with MET Exon 14 Skipping Mutation
por: Brazel, Danielle, et al.
Publicado: (2022)

Non-small-cell lung cancer: how to manage MET exon 14 skipping mutant disease
por: Blaquier, Juan Bautista, et al.
Publicado: (2022)

MET immunochemistry: a reliable screening tool for MET exon 14 skipping mutations in non-small cell lung cancer?
por: Pruis, Melinda A., et al.
Publicado: (2020)

MET exon 14 skipping defines a unique molecular class of non-small cell lung cancer
por: Zheng, Difan, et al.
Publicado: (2016)

MET exon 14 skipping mutations and gene amplification in a Taiwanese lung cancer population
por: Lung, Jrhau, et al.
Publicado: (2019)

MET exon 14 skipping is overexpressed in an allele-specific manner in lung adenocarcinoma primary samples
por: Durham, Megan, et al.
Publicado: (2023)

Use of savolitinib as neoadjuvant therapy for non–small cell lung cancer patient with MET exon 14 skipping alterations: A case report
por: Zhang, Yu, et al.
Publicado: (2022)

Clinicopathological characteristics of Non-Small Cell Lung Cancer (NSCLC) patients with c-MET exon 14 skipping mutation, MET overexpression and amplification
por: Ding, Caixia, et al.
Publicado: (2023)

Characterization of Non–Small-Cell Lung Cancers With MET Exon 14 Skipping Alterations Detected in Tissue or Liquid: Clinicogenomics and Real-World Treatment Patterns
por: Lee, Jessica K., et al.
Publicado: (2021)

Durable Response to Chemoimmunotherapy of a Lung Adenocarcinoma Harboring a MET Exon 14 Skipping Mutation
por: Nitta, Naohiro, et al.
Publicado: (2023)

MET Exon 14 Skipping Mutations in Non–Small-Cell Lung Cancer: An Overview of Biology, Clinical Outcomes, and Testing Considerations
por: Socinski, Mark A., et al.
Publicado: (2021)

Tepotinib Treatment in Patients With MET Exon 14–Skipping Non–Small Cell Lung Cancer: Long-term Follow-up of the VISION Phase 2 Nonrandomized Clinical Trial
por: Mazieres, Julien, et al.
Publicado: (2023)

Tepotinib Efficacy and Safety in Patients with MET Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice
por: Le, Xiuning, et al.
Publicado: (2022)

Activity and bioavailability of tepotinib for leptomeningeal metastasis of NSCLC with MET exon 14 skipping mutation
por: Tanaka, Hisashi, et al.
Publicado: (2021)

Clinical and pathological characteristics of 11 NSCLC patients with c-MET exon 14 skipping
por: Chen, Hualin, et al.
Publicado: (2022)

MET Amplification as a Resistance Driver to TKI Therapies in Lung Cancer: Clinical Challenges and Opportunities
por: Qin, Kang, et al.
Publicado: (2023)

Dramatic intracranial response to tepotinib in a patient with lung adenocarcinoma harboring MET exon 14 skipping mutation
por: Takamori, Shinkichi, et al.
Publicado: (2021)

Capmatinib in MET Exon 14 Skipping Mutation-Positive Lung Adenocarcinoma with Extensive Central Nervous System Metastasis
por: Kim, Tae Woo, et al.
Publicado: (2022)

The Clinical Impact of Capmatinib in the Treatment of Advanced Non–Small Cell Lung Cancer with MET Exon 14 Skipping Mutation or Gene Amplification
por: Choi, Wonyoung, et al.
Publicado: (2021)

Real-World Experience in Treatment of Patients with Non-Small-Cell Lung Cancer with BRAF or cMET Exon 14 Skipping Mutations
por: Janzic, Urska, et al.
Publicado: (2023)

Characterization of MET Exon 14 Skipping Alterations (in NSCLC) and Identification of Potential Therapeutic Targets Using Whole Transcriptome Sequencing
por: Kim, So Yeon, et al.
Publicado: (2022)

Recurrent PTPRZ1‐MET fusion and a high occurrence rate of MET exon 14 skipping in brain metastases
por: Chai, Rui‐Chao, et al.
Publicado: (2021)

Prognosis and Concurrent Genomic Alterations in Patients With Advanced NSCLC Harboring MET Amplification or MET Exon 14 Skipping Mutation Treated With MET Inhibitor: A Retrospective Study
por: Liu, Li, et al.
Publicado: (2021)

Transient asymptomatic pulmonary opacities in a patient with MET exon 14 skipping non‐small cell lung cancer: A case report
por: Ikeo, Satoshi, et al.
Publicado: (2023)

Long-Term Efficacy, Safety, and Subgroup Analysis of Savolitinib in Chinese Patients With NSCLCs Harboring MET Exon 14 Skipping Alterations
por: Lu, Shun, et al.
Publicado: (2022)

Capmatinib in Japanese patients with MET exon 14 skipping–mutated or MET‐amplified advanced NSCLC: GEOMETRY mono‐1 study
por: Seto, Takashi, et al.
Publicado: (2021)

Interstitial lung disease associated with capmatinib therapy in a patient with non‐small cell lung cancer harboring a skipping mutation of MET exon 14
por: Kanemura, Hiroaki, et al.
Publicado: (2020)

Integrative genomic analysis of drug resistance in MET exon 14 skipping lung cancer using patient-derived xenograft models
por: Xu, Yunhua, et al.
Publicado: (2022)

Matching-Adjusted Indirect Comparison (MAIC) of Tepotinib with Other MET Inhibitors for the Treatment of Advanced NSCLC with MET Exon 14 Skipping Mutations
por: Paik, Paul K., et al.
Publicado: (2022)

Validation of the Idylla GeneFusion assay to detect fusions and MET exon-skipping in non-small cell lung cancers
por: Gilson, Pauline, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_09g04l8kqr454dlcvgl51lmp6h